Today I will talk about TOYO INK, a leading printing ink manufacturer in Japan.
It is a chemical manufacturer that mainly handles Colorants & Functional Materials, Polymers & Coatings.
※The above images are from TOYO INK’s website
TOYO INK is a long-established company founded in 1896 and is now a global company with more than 8,000 employees in 24 countries and regions.
Their main products are printing inks for packages and colorants for various plastic products.
In addition, they further expanded their scope of business into the semiconductor market and into the pharmaceutical industry as a manufacturer and marketer of transdermal drug delivery systems since 2016.
￥2,046 （4/23 last closing price)
The latest stock price ← click here Trading unit: 100
The final month of the settlement: December
Dividend yield 4.40 %
PER 15.94 PBR 0.57
Equity ratio 56.2 %
Demand for package printing for food packaging is stable. Also, demand for electronics will grow for 5G.
Although sales volume decreased in the previous fiscal year, profits were secured by reducing fixed costs.
Printing inks for this term are expected to continue to decline.
Still coating materials for smartphones and colorants for automobiles are expected to get back on track.
TOYO INK SC HD special benefits ← Click here for details
Transition of business results
|
|
Net sales |
Operating profit |
Net profit |
Net profit per share |
dividend |
Dividend payout ratio |
|
2018.12 |
290,208 |
15,276 |
11,847 |
202.9 |
85 |
42% |
|
2019.12 |
279,892 |
13,174 |
8,509 |
145.7 |
90 |
62% |
|
2020.12 |
257,675 |
12,909 |
6,019 |
103.6 |
90 |
87% |
|
2021.12 |
270,000 |
14,000 |
7,500 |
134.4 |
90 |
67% |
※Unit of sales, operating profit, net income is one-million yen
※The figure for December 2021 is the predicted value
|
Cash flow statement |
2020.12 |
2019.12 |
|
CF operating activities |
167 |
196 |
|
CF investing activities |
▲133 |
▲104 |
|
CF financing activities |
162 |
▲62 |
※One unit is one hundred million yen
Note: You should be responsible for your own investment. Please make your own final judgment.